公开(公告)号：US12060433B2

公开(公告)日：2024-08-13

申请号：US17138306

申请日：2020-12-30

Applicant: Incyte Corporation

Inventor： Horacio G. Nastri ,  Shaun M. Stewart ,  Juan Carlos Almagro ,  Jing Zhou ,  Rebecca A. Buonpane ,  Hui Wang ,  Yingnan Chen ,  Xiaozhao Wang ,  Peter Niels Carlsen ,  Yong Li ,  Chao Qi ,  Liangxing Wu ,  Wenqing Yao ,  Wenyu Zhu ,  Taisheng Huang

IPC: C07K16/28 ,  A61K31/135 ,  A61K31/4985 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K31/135 ,  A61K31/4985 ,  A61P35/00 ,  A61K2039/505

Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.

公开(公告)号：US12030884B2

公开(公告)日：2024-07-09

申请号：US17937106

申请日：2022-09-30

Applicant: INCYTE CORPORATION

Inventor： Wenyu Zhu ,  Xiaozhao Wang ,  Wenqing Yao

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

公开(公告)号：US12030883B2

公开(公告)日：2024-07-09

申请号：US17933660

申请日：2022-09-20

Applicant: Incyte Corporation

Inventor： Peter Carlsen ,  Ken Mukai ,  Haolin Yin ,  Xiaozhao Wang ,  Wenqing Yao ,  Wenyu Zhu

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

公开(公告)号：US20230226040A1

公开(公告)日：2023-07-20

申请号：US17991482

申请日：2022-11-21

Applicant: Incyte Corporation

Inventor： Alejandro Amador Arjona ,  Angela Abdollahi ,  Margaret Favata ,  Jonathan Rios-Doria ,  Hui Wang ,  Susan Wee ,  Pei Gan ,  Jeffrey C. Yang ,  Yong Li ,  Le Zhao ,  Chunhong He ,  Chunyin Marshall Law ,  Wenyu Zhu ,  Xiaozhao Wang ,  Wenqing Yao ,  Peter Niels Carlsen ,  Fenglei Zhang ,  Qinda Ye ,  Matthew S. McCammant ,  Rocco Policarpo ,  Artem Shvartsbart ,  Jeremy Roach ,  Gia Hoang ,  Bin Hu ,  Gencheng Li ,  Robert Susick ,  Padmaja Polam ,  Chao Qi ,  Alexander Sokolsky ,  Haolin Yin ,  Chang Min

IPC: A61K31/4745 ,  A61P35/00 ,  A61P11/00 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/498 ,  A61K31/506 ,  A61K45/06

CPC classification number: A61K31/4745 ,  A61P35/00 ,  A61P11/00 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/498 ,  A61K31/506 ,  A61K45/06

Abstract: The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.

公开(公告)号：US11207302B2

公开(公告)日：2021-12-28

申请号：US16849610

申请日：2020-04-15

Applicant: Incyte Corporation ,  Incyte Holdings Corporation

Inventor： Andrew P. Combs ,  Eddy W. Yue ,  Richard B. Sparks ,  Wenyu Zhu ,  Jiacheng Zhou ,  Qiyan Lin ,  Lingkai Weng ,  Tai-Yuen Yue ,  Pingli Liu

IPC: A61K31/4245 ,  C07D271/08 ,  A61K39/395 ,  C07D413/12 ,  C07D413/04

Abstract: The present invention is directed to 1, 2, 5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2, 3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1, 2, 5-oxadiazole derivatives.

公开(公告)号：US20210230294A1

公开(公告)日：2021-07-29

申请号：US17138306

申请日：2020-12-30

Applicant: Incyte Corporation

Inventor： Horacio G. Nastri ,  Shaun M. Stewart ,  Juan Carlos Almagro ,  Jing Zhou ,  Rebecca A. Buonpane ,  Hui Wang ,  Yingnan Chen ,  Xiaozhao Wang ,  Peter Niels Carlsen ,  Yong Li ,  Chao Qi ,  Liangxing Wu ,  Wenqing Yao ,  Wenyu Zhu ,  Taisheng Huang

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/135 ,  A61K31/4985

Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.

公开(公告)号：US20210107900A1

公开(公告)日：2021-04-15

申请号：US16996507

申请日：2020-08-18

Applicant: Incyte Corporation

Inventor： Liangxing Wu ,  Jingwei Li ,  Chao Qi ,  Fenglei Zhang ,  Zhenwu Li ,  Wenyu Zhu ,  Zhiyong Yu ,  Kaijiong Xiao ,  Liang Lu ,  Song Mei ,  Ding-Quan Qian ,  Chunhong He ,  Yingda Ye ,  Meizhong Xu ,  Wenqing Yao

IPC: C07D413/14 ,  C07D471/04 ,  A61P37/02 ,  C07D498/04 ,  C07D513/04 ,  C07D487/04 ,  A61K31/4375 ,  C07D413/06 ,  C07D413/12 ,  A61P37/00

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20180179202A1

公开(公告)日：2018-06-28

申请号：US15850985

申请日：2017-12-21

Applicant: Incyte Corporation

Inventor： Liangxing Wu ,  Neil Lajkiewicz ,  Chunhong He ,  Kaijiong Xiao ,  Wenyu Zhu ,  Zhenwu Li ,  Song Mei ,  Chao Qi ,  Leah C. Konkol ,  Wenqing Yao

IPC: C07D471/04 ,  C07D519/00 ,  A61P37/02

CPC classification number: C07D471/04 ,  A61P37/00 ,  A61P37/02 ,  C07D401/04 ,  C07D519/00

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20160024109A1

公开(公告)日：2016-01-28

申请号：US14873078

申请日：2015-10-01

Applicant: Incyte Corporation ,  Incyte Holdings Corporation

Inventor： Yun-Long Li ,  Wenyu Zhu ,  Song Mei ,  Joseph Glenn

IPC: C07D495/14

CPC classification number: C07D495/14 ,  A61K31/437 ,  C07D495/12

Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

公开(公告)号：US08822511B2

公开(公告)日：2014-09-02

申请号：US14033117

申请日：2013-09-20

Applicant: Incyte Corporation

Inventor： Andrew P. Combs ,  Eddy W. Yue ,  Richard B. Sparks ,  Wenyu Zhu

IPC: A61K31/4245 ,  C07D413/12 ,  C07D271/08

CPC classification number: A61K31/4245 ,  A61K39/0011 ,  A61K39/3955 ,  C07D271/08 ,  C07D413/04 ,  C07D413/12

Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.

Abstract translation: 本发明涉及1,2,5-恶二唑衍生物及其组合物，其为吲哚胺2,3-双加氧酶的抑制剂，可用于治疗癌症和其它疾病，以及其用于治疗癌症和其它疾病的方法和中间体 制备这样的1,2,5-恶二唑衍生物。